The role of il-7 in immunity and cancer

Anticancer Research

Volumn 37, Issue 3, 2017, Pages 963-967

  Lin, Jack ^a   Zhu, Ziwen ^b   Xiao, Huaping ^a,c   Wakefield, Mark R ^b   Ding, Vivi A ^a   Bai, Qian ^b   Fang, Yujiang ^a,b  

^a Des Moines University College of Osteopathic Medicine   (United States)

^b University of Missouri   (United States)

^c XIANGNAN UNIVERSITY   (China)

Author keywords

IL 7; Immunity cancer; Review

Indexed keywords

INTERLEUKIN 7; ACID PHOSPHATASE; ACID PHOSPHATASE PROSTATE ISOENZYME; ANTINEOPLASTIC AGENT; IL7 PROTEIN, HUMAN;

B LYMPHOCYTE; CELL CYCLE ARREST; CELL MATURATION; HUMAN; IMMUNOCOMPETENT CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; ANIMAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOLOGY; GENE REARRANGEMENT; IMMUNE SYSTEM; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASM; PHYSIOLOGY; PROMOTER REGION;

ACID PHOSPHATASE; ANIMALS; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE REARRANGEMENT; HUMANS; IMMUNE SYSTEM; INTERLEUKIN-7; LYMPHOCYTE ACTIVATION; NEOPLASMS; PROMOTER REGIONS, GENETIC; T-LYMPHOCYTES;

EID: 85015810846     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: 10.21873/anticanres.11405     Document Type: Review

References (55)

1. Fiorentino DF, Bond MW and Mosmann T: Two types of mouse t helper cell. Iv. Th2 clones secrete a factor that inhibits cytokine production by th1 clones. J Exp Med 170(6): 2081-2095, 1989.
2. Kondo M, Takeshita T, Higuchi M, Nakamura M, Sudo T, Nishikawa S-L and Sugamura K: Functional participation of the il-2 receptor gamma chain in il-7 receptor complexes. Science 263(5152): 1453-1454, 1994.
3. Noguchi M, Nakamura Y, Russell SM, Ziegler SF, Tsang M, Cao X and Leonard WJ: Interleukin-2 receptor gamma chain: A functional component of the interleukin-7 receptor. Science 262(5141): 1877-1880, 1993.
4. Ziegler SF, Morella KK, Anderson D, Kumaki N, Leonard WJ, Cosman D and Baumann H: Reconstitution of a functional interleukin (il)-7 receptor demonstrates that the il-2 receptor ? chain is required for il-7 signal transduction. Eur J Immunol 25(2): 399-404, 1995.
5. Asao H, Okuyama C, Kumaki S, Ishii N, Tsuchiya S, Foster D and Sugamura K: Cutting edge: The common chain is an indispensable subunit of the il-21 receptor complex. J Immunol 167(1): 1-5, 2001.
6. Ozaki K, Kikly K, Michalovich D, Young PR and Leonard WJ: Cloning of a type i cytokine receptor most related to the il-2 receptor ? chain. Proc Natl Acad Sci USA 97(21): 11439-11444, 2000.
7. Bazdar DA, Kalinowska M, Panigrahi S and Sieg SF: Recycled il-7 can be delivered to neighboring t cells. J Immunol 194(10): 4698-4704, 2015.
8. Fisher A, Burdet C, Bunce C, Merkenschlager M and Ceredig R: Lymphoproliferative disorders in il-7 transgenic mice: Expansion of immature b cells which retain macrophage potential. Int Immunol 7(3): 415-423, 1995.
9. Mertsching E, Meyer V, Linares J, Lombard-Platet S and Ceredig R: Interleukin-7, a non-redundant potent cytokine whose over-expression massively perturbs b-lymphopoiesis. Int Rev Immunol 16(3-4): 285-308, 1998.
10. Valenzona H, Pointer R, Ceredig R and Osmond D: Prelymphomatous b cell hyperplasia in the bone marrow of interleukin-7 transgenic mice: Precursor b cell dynamics, microenvironmental organization and osteolysis. Exp Hematol 24(13): 1521-1529, 1996.
11. Puel A, Ziegler SF, Buckley RH and Leonard WJ: Defective il7r expression in t-b+ nk+ severe combined immunodeficiency. Nat Genet 20(4): 394-397, 1998.
12. Kohn LA, Hao Q-L, Sasidharan R, Parekh C, Ge S, Zhu Y, Mikkola HK and Crooks GM: Lymphoid priming in human bone marrow begins before expression of cd10 with up-regulation of l-selectin. Nat Immunol 13(10): 963-971, 2012.
13. Damia G, Komschlies KL, Faltynek CR, Ruscetti FW and Wiltrout RH: Administration of recombinant human interleukin-7 alters the frequency and number of myeloid progenitor cells in the bone marrow and spleen of mice. Blood 79(5): 1121-1129, 1992.
14. Komschlies KL, Gregorio TA, Gruys ME, Back TC, Faltynek CR and Wiltrout RH: Administration of recombinant human il-7 to mice alters the composition of b-lineage cells and t cell subsets, enhances t cell function, and induces regression of established metastases. J Immunol 152(12): 5776-5784, 1994.
15. Morrissey PJ, Conlon P, Braddy S, Williams DE, Namen AE and Mochizuki DY: Administration of il-7 to mice with cyclophosphamide-induced lymphopenia accelerates lymphocyte repopulation. J Immunol 146(5): 1547-1552, 1991.
16. Namen AE, Schmierer AE, March CJ, Overell RW, Park LS, Urdal DL and Mochizuki DY: B cell precursor growth-promoting activity. Purification and characterization of a growth factor active on lymphocyte precursors. J Exp Med 167(3): 988-1002, 1988.
17. Malaspina A, Moir S, Ho J, Wang W, Howell ML, O'Shea MA, Roby GA, Rehm CA, Mican JM and Chun T-W: Appearance of immature/transitional b cells in hiv-infected individuals with advanced disease: Correlation with increased il-7. Proc Natl Acad Sci USA 103(7): 2262-2267, 2006.
18. Dittel BN and LeBien TW: The growth response to il-7 during normal human b cell ontogeny is restricted to b-lineage cells expressing cd34. J Immunol 154(1): 58-67, 1995.
19. Corcoran A, Smart F, Cowling R, Crompton T, Owen M and Venkitaraman A: The interleukin-7 receptor alpha chain transmits distinct signals for proliferation and differentiation during b lymphopoiesis. EMBO J 15(8): 1924, 1996.
20. Ghia P, Gratwohl A, Signer E, Winkler TH, Melchers F and Rolink AG: Immature b cells from human and mouse bone marrow can change their surface light chain expression. Eur J Immunol 25(11): 3108-3114, 1995.
21. Hertz M and Nemazee D: Bcr ligation induces receptor editing in igm+ igd? bone marrow b cells in vitro. Immunity 6(4): 429-436, 1997.
22. Rolink A, Grawunder U, Haasner D, Strasser A and Melchers F: Immature surface ig+ b cells can continue to rearrange kappa and lambda l chain gene loci. J Exp Med 178(4): 1263-1270, 1993.
23. Han S, Dillon SR, Zheng B, Shimoda M, Schlissel MS and Kelsoe G: V (d) j recombinase activity in a subset of germinal center b lymphocytes. Science 278(5336): 301-305, 1997.
24. Papavasiliou F, Casellas R, Suh H, Qin X-F, Besmer E, Pelanda R, Nemazee D, Rajewsky K and Nussenzweig MC: V (d) j recombination in mature b cells: A mechanism for altering antibody responses. Science 278(5336): 298-301, 1997.
25. Rodewald H-R and Fehling HJ: Molecular and cellular events in early thymocyte development. Adv Immunol 69: 1-112, 1998.
26. Lefrançois L and Puddington L: Extrathymic intestinal t-cell development: Virtual reality? Immunol Today 16(1): 16-21, 1995.
27. Patel ES, Okada S, Hachey K, Yang L-j, Durum SK, Moreb JS and Chang L-J: Regulation of in vitro human t cell development through interleukin-7 deprivation and anti-cd3 stimulation. BMC Immunol 13(1): 46, 2012.
28. Yu Q, Erman B, Park J-H, Feigenbaum L and Singer A: Il-7 receptor signals inhibit expression of transcription factors tcf-1, lef-1, and ror?t impact on thymocyte development. J Exp Med 200(6): 797-803, 2004.
29. Haas J, Korporal M, Schwarz A, Balint B and Wildemann B: The interleukin-7 receptor ? chain contributes to altered homeostasis of regulatory t cells in multiple sclerosis. Eur J Immunol 41(3): 845-853, 2011.
30. Kerzerho J, McIlvaine EJ, Anthony P, Mack WJ, Wang C-H, Frederick T, Operskalski E, Chen Z, Al-Harthi L and Landay A: Impact of hepatitis c virus on the circulating levels of il-7 in hiv-1 coinfected women. JAIDS J Acq Imm Def 71(2): 172-180, 2016.
31. Morre M and Beq S: Interleukin-7 and immune reconstitution in cancer patients: A new paradigm for dramatically increasing overall survival. Target Oncol 7(1): 55-68, 2012.
32. Suda T and Zlotnik A: Il-7 maintains the t cell precursor potential of cd3-cd4-cd8-thymocytes. J Immunol 146(9): 3068-3073, 1991.
33. Kim K, Lee C-k, Sayers TJ, Muegge K and Durum SK: The trophic action of il-7 on pro-t cells: Inhibition of apoptosis of pro-t1,-t2, and-t3 cells correlates with bcl-2 and bax levels and is independent of fas and p53 pathways. J Immunol 160(12): 5735-5741, 1998.
34. von Freeden-Jeffry U, Solvason N, Howard M and Murray R: The earliest t lineage-committed cells depend on il-7 for bcl-2 expression and normal cell cycle progression. Immunity 7(1): 147-154, 1997.
35. Maraskovsky E, O'Reilly LA, Teepe M, Corcoran LM, Peschon JJ and Strasser A: Bcl-2 can rescue t lymphocyte development in interleukin-7 receptor-deficient mice but not in mutant rag-1?/? mice. Cell 89(7): 1011-1019, 1997.
36. Akashi K, Kondo M, von Freeden-Jeffry U, Murray R and Weissman IL: Bcl-2 rescues t lymphopoiesis in interleukin-7 receptor-deficient mice. Cell 89(7): 1033-1041, 1997.
37. Huang J, Durum SK and Muegge K: Cutting edge: Histone acetylation and recombination at the tcr? locus follows il-7 induction. J Immunol 167(11): 6073-6077, 2001.
38. Ye S-K, Agata Y, Lee H-C, Kurooka H, Kitamura T, Shimizu A, Honjo T and Ikuta K: The il-7 receptor controls the accessibility of the tcr? locus by stat5 and histone acetylation. Immunity 15(5): 813-823, 2001.
39. Fritzell S, Eberstål S, Sandén E, Visse E, Darabi A and Siesjö P: Ifn? in combination with il-7 enhances immunotherapy in two rat glioma models. J Neuroimmunol 258(1): 91-95, 2013.
40. Alderson MR, Tough TW, Ziegler SF and Grabstein KH: Interleukin 7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes. J Exp Med 173(4): 923-930, 1991.
41. Lynch DH, Namen AE and Miller RE: In vivo evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti-tumor cytotoxic t lymphocytes. Eur J Immunol 21(12): 2977-2985, 1991.
42. Colombetti S, Lévy F and Chapatte L: Il-7 adjuvant treatment enhances long-term tumor antigen-specific cd8+ t-cell responses after immunization with recombinant lentivector. Blood 113(26): 6629-6637, 2009.
43. Zenatti PP, Ribeiro D, Li W, Zuurbier L, Silva MC, Paganin M, Tritapoe J, Hixon JA, Silveira AB and Cardoso BA: Oncogenic il7r gain-of-function mutations in childhood t-cell acute lymphoblastic leukemia. Nat Genet 43(10): 932-939, 2011.
44. Fujio K, Watanabe M, Ueki H, Li S-A, Kinoshita R, Ochiai K, Futami J, Watanabe T, Nasu Y and Kumon H: A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment. Oncol Rep 33(4): 1585-1592, 2015.
45. Boukhari A, Alhosin M, Bronner C, Sagini K, Truchot C, Sick E, Schini-Kerth VB, Andre P, Mely Y and Mousli M: Cd47 activation-induced uhrf1 over-expression is associated with silencing of tumor suppressor gene p16ink4a in glioblastoma cells. Anticancer Res 35(1): 149-157, 2015.
46. Merchant MS, Bernstein D, Amoako M, Baird K, Fleisher TA, Morre M, Steinberg SM, Sabatino M, Stroncek DF and Venkatesan AM: Adjuvant immunotherapy to improve outcome in high risk pediatric sarcomas. Clin Cancer Res 22(13): 3182-3191, 2016.
47. Johnson CB, Riesenberg BP, May BR, Gilreath SC, Li G, Staveley-O'Carroll KF, Garrett-Mayer E, Mehrotra S, Cole DJ and Rubinstein MP: Effector cd8+ t-cell engraftment and antitumor immunity in lymphodepleted hosts is il7r? dependent. Cancer Immunol Res 3(12): 1364-1374, 2015.
48. Chandran SS, Paria BC, Srivastava AK, Rothermel LD, Stephens DJ and Kammula US: Tumor-specific effector cd8+ t cells that can establish immunological memory in humans after adoptive transfer are marked by expression of il7 receptor and c-myc. Cancer Res 75(16): 3216-3226, 2015.
49. Leen AM, Sukumaran S, Watanabe N, Mohammed S, Keirnan J, Yanagisawa R, Anurathapan U, Rendon D, Heslop HE, Rooney CM, Brenner MK and Vera JF: Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther 22(6): 1211-1220, 2014.
50. Perna S, Pagliara D, Mahendravada A, Liu H, Brenner M and Savoldo B: Interleukin-7 mediates selective expansion of tumorredirected cytotoxic t lymphocytes (ctls) without enhancement of regulatory t-cell inhibition. Clin Cancer Res 20(1): 131-139, 2014.
51. Pellegrini M, Calzascia T, Elford AR, Shahinian A, Lin AE, Dissanayake D, Dhanji S, Nguyen LT, Gronski MA and Morre M: Adjuvant il-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med 15(5): 528-536, 2009.
52. Li B, VanRoey MJ and Jooss K: Recombinant il-7 enhances the potency of gm-csf-secreting tumor cell immunotherapy. Clin Immunol 123(2): 155-165, 2007.
53. Liu Z-H, Wang M-H, Ren H-J, Qu W, Sun L-M, Zhang Q-F, Qiu X-S and Wang E-H: Interleukin 7 signaling prevents apoptosis by regulating bcl-2 and bax via the p53 pathway in human nonsmall cell lung cancer cells. Int J Clin Exp Pathol 7(3): 870, 2014.
54. Park SL, Lee E-J, Kim W-J and Moon S-K: P27kip1 is involved in erk1/2-mediated mmp-9 expression via the activation of nf?b binding in the il-7-induced migration and invasion of 5637 cells. Int J Oncol 44(4): 1349-1356, 2014.
55. Ming J, Zhang Q, Jiang Y, Jiang G and Qiu X: Interleukin 7 and its receptor promote cell proliferation and induce lymphangiogenesis in non-small cell lung cancer. Zhonghua Bing Li Xue Za Zhi 41(8): 511-518, 2012.